Dr. Jean Berthelet

PostDoc

 

Born in Beaune, France, I studied Biochemistry and Cellular and Molecular Biology at the University of Dijon. After obtaining my Master´s degree, I joined the lab of Prof. Laurence Dubrez to study the protein cIAP and its role in cell proliferation and cytoskeleton remodelling. Another focus of my work was the regulation of the Rho GTPase cdc42 by cIAP and its influence on cell motility and cancer cell invasion. I received my PhD in Biochemistry and Cellular and Molecular Biology from Burgundy University, Dijon, France in 2014. In July 2015, I joined Prof. Rajalingam´s group as a Postdoctoral fellow to study new targets in Papillary Thyroid Carcinoma.

 

 

Education

 

2015- present                Postdoctoral fellow in the lab of Prof. Rajalingam, MSU at the Institute for
                                         Immunology, Unimedizin Mainz

 

2010-2014                      PhD in Biochemistry, Cellular and Molecular Biology, Burgundy University,
                                         Dijon, France

 

2008-2010                      Masters Degree in Biochemistry, Cellular and Molecular Biology,  

                                         Burgundy, University, Dijon, France

 

2003-2007                      Bachelors Degree in Biochemistry, Cellular and Molecular Biology,
                                         Burgundy University, Dijon, France

 

 

Publications

 

•  Marivin A*, Berthelet J*, Cartier J, Paul C, Gemble S, Morizot A, Boireau W, Saleh M, Bertoglio   J, Solary E, Dubrez L. cIAP1 regulates TNF-mediated cdc42 activation and filopodia  formation.  Oncogene. 2013 Nov 25. (* shared first authorship)

 

• Dubrez L, Marivin A, Berthelet J. [IAP and Rho finally connected]. Med Sci (Paris). 2014 Mar;30(3):231-3. doi: 10.1051/medsci/20143003003. Epub 2014 Mar 31. French. 

   

•  Largeot A, Paggetti J, Broséus J, Aucagne R, Lagrange B, Martin RZ, Berthelet J, Quéré R,      

        Lucchi G, Ducoroy P, Bastie JN, Delva L. Symplekin, a polyadenylation factor, prevents MOZ
        and MLL activity on HOXA9 in hematopoietic cells. Biochim Biophys Acta. 2013 Dec.

 

•  Dubrez L, Berthelet J, Glorian V. IAP proteins as targets for drug development in  oncology. Onco Targets Ther. 2013 Sep 16;9:1285-304. doi: 10.2147/OTT.S33375. Review.

 

•  Berthelet J, Dubrez L. Regulation of Apoptosis by Inhibitors of Apoptosis (IAPs). Cells. 2013  Mar 14;2(1):163-87. doi: 10.3390/cells2010163.

 

•  Cartier J, Marivin A, Berthelet J, Dubrez L. [IAPs: a central element in the NF-κB activating  signaling pathway]. Med Sci (Paris). 2012 Jan;28(1):69-75. doi: 10.1051/medsci/2012281019.  Epub 2012 Jan 27. Review. French.

 

•  Marivin A, Berthelet J, Plenchette S, Dubrez L. The Inhibitor of Apoptosis (IAPs) in Adaptive  Response to Cellular Stress. Cells. 2012 Oct 10;1(4):711-37. doi: 10.3390/cells1040711

 

•  Cartier J*, Berthelet J*, Marivin A, Gemble S, Edmond V, Plenchette S, Lagrange B, Hammann

        A, Dupoux A, Delva L, Eymin B, Solary E, Dubrez L. Cellular inhibitor of apoptosis protein-1
        (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription. J Biol
        Chem. 2011 Jul 29. (* shared first authorship)